We are pleased to announce that EvergreenHealth was awarded a $10,000 grant from the Michael J. Fox Foundation (MJFF) for Parkinson's Research.
Dr. Pinky Agarwal, MD, FAAN, movement disorders neurologist at the Booth Gardner Parkinson’s Care Center,explains how the grant will be used and the impact it will have on the Parkinson’s Disease (PD) community.
The Michael J. Fox Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
The MJFF grant will help Dr. Agarwal continue her research on the health disparities experienced by ethnic and minority populations, women and those with limited English proficiency (LEP).
She is an active advocate for increased representation of ethnic and minority populations in clinical research, recognizing that increased minority representation improves generalizability of clinical research results in Parkinson’s Disease.
During her work at EvergreenHealth, which treats patients of diverse backgrounds, ethnicities and languages, Dr. Agarwal developed an interest in engaging underrepresented groups in clinical research. In her new role as the co-chair of the Health/Care Outcomes and Disparities Working Group of the Parkinson’s Study Group (PSG), she intends to continue her work in improving minority engagement in clinical trials.
Prior to receiving the MJFF grant, Dr. Agarwal; Sudeshna Ray, MBBS; and EvergreenHealth Research team have presented posters at national meetings and published in peer-reviewed journals, highlighting health disparities in clinical research.
The first steps in use of the grant will be to enroll approximately 80 PD patients from Booth Gardner Parkinson’s Care Center at EvergreenHealth into Fox Insight, which is an online study conducted by the MJFF, aiming to provide the research community with insight into the lived experience, the genetics and the variability of Parkinson's disease.
Understanding patients’ perceptions about participation in clinical research is of critical importance to increased enrollment, which in turn can speed up availability of new therapeutics for the Parkinson’s disease community.